Concepedia

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

Raymond Y. Huang, Rifaquat Rahman, Karla V. Ballman, Sara J. Felten, S. Keith Anderson, Benjamin M. Ellingson, Lakshmi Nayak, Eudocia Q. Lee, Lauren E. Abrey, Evanthia Galanis,

Clinical Cancer Research · 2015 · 74 citations · 17 references

DOIFull text

Open access

Abstract

The inclusion of T2/FLAIR assessment resulted in statistically significant differences in median PFS and ORRs compared with assessment of solely enhancing tumor (Macdonald criteria), although OR and PFS determined by both RANO and Macdonald criteria correlated with OS.

References

17

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21K citations · Full text

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.7K citations · Full text

, , +23

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

, , +20

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

Teri Kreisl, Lyndon Kim, Kraig Moore et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text